Introduction
Phenobarbital (PB) is the oldest antiepileptic drug in common use. Although it is now generally thought to be a second-line therapy, PB is recommended as first-line treatment for partial and generalized tonic-clonic seizures in resource-poor countries. 1 PB also remains one of the most important antiepileptic drugs even in many developed countries, because of its many advantages, including reliability of supply, affordable cost, broad spectrum of action, and ease of use. 2 PB has a reputation for safety, but cognitive and behavioral side-effects which include impaired Seizure (2007) Summary Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease. Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia. At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue. Inflammatory reactions of internal and external hepatic biliary ducts were also seen. Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences. For this reason, each clinician should recognize this entity in the differential diagnosis of PB-related asymptomatic chronic hepatic enzyme dysfunction. # 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. cognition, sedation, depression and agitation, are reasons for great concern.
2 In addition, PB may occasionally make serum aminotransferase levels increase; but it is commonly believed that these laboratory changes do not indicate or predict the development of significant chronic liver disease. 3 Nonetheless, the clinical implication of drugrelated hepatotoxicity is its potential to progress to liver failure. 4 Although hepatotoxicity related to PB seems to be uncommon, its true incidence might be much higher and more severe than is commonly thought, because of the difficulty in attributing even severe cases of hepatocellular injury to drugs. 4 Here we report two cases of chronic liver damage with a mixed pattern of hepatonecrosis and colangitis related to long-term PB treatment. Both adult patients had a long history of epilepsy treated with PB, but the cause of sudden death was related neither to liver failure nor to epilepsy, but to cardiac arrest in one patient, and acute bronchopneumonia in the other.
Case reports Patient 1
The patient was a 44-year-old man with no family history of either epilepsy or febrile convulsions and normal psychomotor development. At the age of 13 years, he developed sporadic secondarily generalized tonic-clonic seizures, which disappeared after treatment with a combination of PB and phenytoin. The latter drug was stopped after 1 year, and the patient remained on monotherapy with PB. Serum levels had been within normal ranges on repeated controls over the years. The most recent blood investigation revealed a moderate elevation of serum aminotransferase levels but no evidence of viral hepatitis. There was no history of alcohol abuse or drug addiction. He was only moderately overweight. His brain MRI study showed no obvious abnormalities. On the day of his sudden death he was working without any evident clinical problems. During work, he suddenly fell down with a cardiorespiratory arrest. The emergency service arrived within a few minutes, but cardio pulmonary resuscitation was unsuccessful.
At autopsy, no acute lesions were found. Heart weighed 320 g, and there were several areas of myocardial fibrosis. The coronary arteries' internal diameter were generally reduced by arteriosclerosis ''medio-intimal'' deposits and some coronary sub-epicardial vessels presented a lumen reduction of about 50%. Both lungs were congested and edematous, with interstitial fibrosis and evidence of alveolar inflammatory infiltrates rich in serum and serum protein fluid, mixed with granulocytes, macrophages and erythrocytes.
Analysis of liver parenchyma revealed a rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells. Importantly, there were several large macro foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue (Fig. 1A) . Inflammatory reactions of internal and external hepatic biliary ducts were also seen (Fig. 1B) . The necrotic material was stained for mycetes using Mac Manus, Gomori Groccot, PAS and Alcian bleu but did not show any hypha or spore of mycetes, such as Candida, Aspergillus or Actynomices.
Toxicological analysis, made by gas chromatography (GLC) analysis and confirmed by gas mass spectrometry analysis (GC-MS), showed therapeutic levels of PB in the blood, urine and bile (15.4 mg/ml, 9.7 mg/ml and 18.9 mg/ml), respectively, while phenytoin or other toxic substances were undetectable.
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Patient 2
This was a 40-year-old man with partial epilepsy that started at the age of 18 years after a meningococcal meningitis infection. His brain MRI study showed no obvious abnormalities. He was on monotherapy with PB with relatively good control of his seizures. There was no history of alcohol abuse or drug addiction. Blood investigation ruled out hepatitis. He died a few days after the onset of severe acute bronchopneumonia, despite receiving immediate and intensive treatment with antibiotics.
At autopsy, analysis of liver parenchyma revealed some areas of hepatonecrosis surrounded by a hard ring of non-specific granulomatous tissue with some inflammatory infiltrate of mixed lymphocytes and monocyte cells (Fig. 2) . Toxicological analysis revealed only therapeutic levels of PB.
Discussion
Our findings illustrate that PB may be associated with chronic liver damage characterized by a mixed pattern of hepatonecrosis and colangitis, which may lead to more serious and deleterious consequences. 4 The risks of long term PB-treated epileptic patients developing liver necrosis are not as well described in the literature as they are for phenytoin. 5 We have identified no definite case reports of PB-induced chronic liver damage in our search of the literature. PB has been found to produce acute hepatonecrosis, 6 while chronic liver enzyme abnormalities associated with PB are attributed to enzyme induction alone, 3 Nonetheless, blood liver tests have a poor predictive value with respect to histologic involvement. 7 In a retrospective analysis of post-mortem liver samples, hepatocellular damage was found in about 50% of patients receiving long-term anticonvulsant therapy. 8 So, although uncommon, each clinician should recognize this entity in the differential diagnosis of PB-related asymptomatic chronic hepatic enzyme dysfunction, especially if vague symptoms such as nausea, fatigue or malaise also occur. 3 We are aware of the pitfalls and caveats of diagnosing the cause of drug-related hepatoxicity, 4 but the facts suggest that that PB directly contributed to produce chronic liver damage in our patients. First, there was the temporal relationship to the adverse event as both patients had long-term exposure to PB. Moreover, thorough clinical and laboratory investigations excluded other causes of liver dysfunction, including viral hepatitis or alcohol abuse. Although patient 1 had also taken phenytoin, it was only for approximately 1 year at the beginning of his epilepsy, so it is unlikely that it played a major role in causing liver damage in that patient. Although patient 2 had consumed other potentially harmful medications, including antibiotics, for only a few days before his death, it cannot be ruled out definitively that these compounds did not contribute to the liver damage. It should be noted, however, that in both patients the histologic findings were highly characteristic of PB hepatotoxicity with a mixed hepatocellular and concurrent cholestatic component. 4 These pathological features discount the role of cardiovascular shock, which is known to produce liver injury, 4 as a contributory factor, since damage to other organs, especially the kidneys, would be expected in this situation.
Nonetheless, the part played by other factors in our patients remains unknown, as drug-related hepatotoxicity cannot be viewed as a single disease, and many different mechanisms lead to hepatotoxicity. 4 For instance, genetic polymorphisms have a strong influence on drug metabolism and may predispose to drug-induced hepatotoxicity. 9 Moreover, adults are generally more susceptible to hepatotoxicity than children, while obesity and malnutrition are also susceptibility factors. 4 Concomitant use of antiepileptic drugs that induce microsomal P450 enzymes, such as PB and phenytoin, may enhance the production of a toxic metabolite, and hence increase the risk of hepatotoxicity with combined therapy. (Hematoxiline and eosin Â240) . Note the areas of hepatonecrosis, which are surrounded by a hard ring of non-specific granulomatous tissue with some inflammatory infiltrate of mixed lymphocytes and monocyte cells.
